Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

NVS vs GSK: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

NVS Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 6–4 Matrix Metrics)

NVS Overall Winner 6-Pillar Tally: NVS 3 – 2 GSK (1 Tie) Matrix Metrics: NVS 6 – 4 GSK

As of Nov 16, 2026, Novartis AG (NVS) is the stronger overall head-to-head candidate over GSK plc (GSK) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). NVS carries a Unified Composite Score of 41.5/100 (SELL) at $161.59 (16.2x Forward P/E, 34.0% operating margin), whereas GSK carries 42.7/100 (HOLD) at $50.77 (10.2x Forward P/E, 30.5% operating margin).

  • Composite vs. Pillar Nuance: While GSK currently prints a higher short-term Unified Composite Score (42.7/100 HOLD vs. NVS 41.5/100 SELL), NVS captures the overall institutional head-to-head verdict (6–4 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (34.0% vs. 30.5% operating margin) and revenue trajectory (+4.7% vs. +4.0% YoY).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About NVS vs GSK
NVS NYSE Head-to-Head Winner
Novartis AG
Pharmaceutical Preparations
$161.59
+0.68% 1D
Market Cap $302.9B
TTM Revenue $40.5B
Forward P/E 16.2x
Beta / 30D Vol 0.31β · 27% Vol
Unified Composite Score
41.5 / 100 SELL
Tech 29.0 Fund 38.0 Flow 50.0 Mom 21.1
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (0.7% over 20 days), RSI 61
RSI-14: 60.8 · SMA20: $159.19 · SMA50: $149.17
GSK NYSE
GSK plc American Depositary Shares (Each representing two Ordinary Shares)
Pharmaceutical Preparations
$50.77
+0.63% 1D
Market Cap $101.5B
TTM Revenue $33.5B
Forward P/E 10.2x
Beta / 30D Vol 0.27β · 30% Vol
Unified Composite Score
42.7 / 100 HOLD
Tech 41.0 Fund 38.0 Flow 50.0 Mom 11.5
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 55
RSI-14: 55.3 · SMA20: $50.33 · SMA50: $49.31

6-Pillar Scorecard Institutional Category Breakdown (NVS 3 – 2 GSK)

Columns: Metric · NVS · GSK
1. Valuation Multiples GSK
Forward P/E 16.2x 10.2x
Trailing P/E 30.6x 17.6x
PEG Ratio 3.81x 6.41x
EV / Revenue 7.5x 3.0x
2. Growth & Scale NVS
Revenue Growth (YoY) +4.7% +4.0%
Earnings Growth (YoY) -68.8% -22.8%
TTM Revenue (USD) $40.5B $33.5B
Market Cap $302.9B $101.5B
3. Profitability & Quality NVS
Gross Margin 75.2% 73.8%
Operating Margin 34.0% 30.5%
Net Profit Margin 17.5% 13.0%
Return on Equity (ROE) 24.3% 28.3%
4. Balance Sheet & Cash Flow NVS
Cash Generation (TTM) $17.0B EBITDA $11.5B EBITDA
Cash Flow Margin 42.0% EBITDA Mgn 34.3% EBITDA Mgn
Net Cash / Leverage $19.71 Book/Sh · 24.3% ROE $12.53 Book/Sh · 28.3% ROE
Dividend Yield 2.96% 3.59%
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile 16.9% (6th %ile) 22.3% (39th %ile)
Put/Call OI Skew Thin ADR Chain Thin ADR Chain
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Neutral
6. R&D & Supply-Chain Moat GSK
OpEx & R&D Intensity 41.2% of Rev ($16.7B) 43.3% of Rev ($14.5B)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat High-Margin Pricing Power Moat High-Margin Pricing Power Moat
Supply-Chain Role Drug Manufacturers - General Operator Drug Manufacturers - General Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: NVS (6) vs GSK (4)
Institutional Metric NVS GSK Criterion Row Edge
Market Capitalization
Scale
$302.9B $101.5B Larger Scale NVS
Trailing P/E Ratio
Valuation
30.6x 17.6x Lower Multiple GSK
Forward P/E Ratio
Valuation
16.2x 10.2x Lower Multiple GSK
Revenue Growth (YoY)
Growth
+4.7% +4.0% Higher Growth NVS
Operating Margin (TTM)
Profitability
34.0% 30.5% Higher Margin NVS
Net Profit Margin
Profitability
17.5% 13.0% Higher Margin NVS
Return on Equity (ROE)
Capital Efficiency
24.3% 28.3% Higher ROE GSK
52-Week Range Position
Momentum
81% ($123–$170) 31% ($46–$62) Stronger Trend NVS
Beta / 30D Volatility
Risk Regime
0.31β · 27% Vol 0.27β · 30% Vol Lower Realized Risk NVS
Unified Institutional Score
Composite Signal
41.5 / 100 (SELL) 42.7 / 100 (HOLD) Higher Composite GSK
Trailing 12M Revenue (USD)
Operating Scale
$40.5B $33.5B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
75.2% 73.8% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
3.81x PEG · 7.5x EV/Rev 6.41x PEG · 3.0x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$17.0B EBITDA ($19.71 Book/Sh · 24.3% ROE) $11.5B EBITDA ($12.53 Book/Sh · 28.3% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon NVS +4.74 pp
NVS: +7.28% · GSK: +2.54%
3M Horizon NVS +5.3 pp
NVS: +4.56% · GSK: -0.74%
6M Horizon NVS +7.33 pp
NVS: +8.34% · GSK: +1.01%
1Y Horizon NVS +17.04 pp
NVS: +22.5% · GSK: +5.46%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on NVS vs GSK. Trailing 12-month operating profitability (NVS 34.0% vs GSK 30.5%) and valuation multiples (NVS 16.2x vs GSK 10.2x Forward P/E) are benchmarked directly in Pillar 4 below.

NVS ADR TTM Benchmark FX-Normalized USD
TTM Revenue$40.5B
Gross Margin75.2%
Op. Margin34.0%
ROE / Fwd P/E24.3% · 16.2x
GSK ADR TTM Benchmark FX-Normalized USD
TTM Revenue$33.5B
Gross Margin73.8%
Op. Margin30.5%
ROE / Fwd P/E28.3% · 10.2x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
NVS UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 16.9%
IV Percentile 6th %ile
Put/Call OI Skew Thin ADR Chain
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact NVS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
GSK UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 22.3%
IV Percentile 39th %ile
Put/Call OI Skew Thin ADR Chain
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact GSK Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
NVS Moat Profile High-Margin Pricing Power Moat
Drug Manufacturers - General Operator
Competes within the Drug Manufacturers - General value chain with $302.9B market capitalization and 34.0% operating margin.
OpEx & R&D Reinvestment 41.2% of Rev ($16.7B)
90D Engineering Disclosures 0 Published
GSK Moat Profile High-Margin Pricing Power Moat
Drug Manufacturers - General Operator
Competes within the Drug Manufacturers - General value chain with $101.5B market capitalization and 30.5% operating margin.
OpEx & R&D Reinvestment 43.3% of Rev ($14.5B)
90D Engineering Disclosures 0 Published

Investor FAQ NVS vs GSK Key Questions & Quantitative Answers

As of Nov 16, 2026, Novartis AG (NVS) is the stronger overall head-to-head candidate over GSK plc (GSK) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). NVS carries a Unified Composite Score of 41.5/100 (SELL) at $161.59 (16.2x Forward P/E, 34.0% operating margin), whereas GSK carries 42.7/100 (HOLD) at $50.77 (10.2x Forward P/E, 30.5% operating margin). Composite vs. Pillar Nuance: While GSK currently prints a higher short-term Unified Composite Score (42.7/100 HOLD vs. NVS 41.5/100 SELL), NVS captures the overall institutional head-to-head verdict (6–4 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (34.0% vs. 30.5% operating margin) and revenue trajectory (+4.7% vs. +4.0% YoY).

NVS leads the Growth & Scale pillar: NVS posts +4.7% YoY revenue growth and -68.8% YoY earnings growth on $40.5B TTM revenue (75.2% gross margin, 34.0% operating margin), compared with GSK at +4.0% YoY revenue growth and -22.8% YoY earnings growth on $33.5B TTM revenue (73.8% gross margin, 30.5% operating margin). On trailing 12-month operating scale, NVS generates $40.5B in USD-normalized revenue versus $33.5B for GSK. In operating R&D and SG&A reinvestment, NVS deploys 41.2% of Rev ($16.7B) (0 90-day corporate R&D disclosures) versus 43.3% of Rev ($14.5B) (0 disclosures) for GSK.

GSK screens cheaper on headline valuation multiples. NVS trades at 16.2x Forward P/E, 30.6x Trailing P/E, 3.81x PEG, and 7.5x EV/Revenue (42.0% EBITDA margin), whereas GSK trades at 10.2x Forward P/E, 17.6x Trailing P/E, 6.41x PEG, and 3.0x EV/Revenue (34.3% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against NVS (24.3% ROE) versus GSK (28.3% ROE) capital efficiency.

In options market volatility and institutional positioning, NVS carries 16.9% implied volatility (6th %ile, Compressed (<25th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.31β · 27% Vol realized risk). By comparison, GSK carries 22.3% implied volatility (39th %ile, Balanced (25th–60th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.27β · 30% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.